Cacace Angela M 4

4 · ARVINAS, INC. · Filed Mar 2, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

Arvinas (ARVN) CSO Angela Cacace Receives RSUs & Option

What Happened

Angela M. Cacace, Chief Scientific Officer of Arvinas, was granted compensation awards on February 26, 2026: 45,000 restricted stock units (RSUs) and a derivative award covering 67,000 shares (reported as an option/derivative). The Form 4 shows an acquisition price of $0.00 for both grants (i.e., the RSUs represent contingent rights to receive shares for no consideration). These are awards/compensation grants rather than open-market purchases or sales.

Key Details

Transaction date: February 26, 2026; Form 4 filed March 2, 2026 (timely filing).
Reported amounts and prices: 45,000 RSUs @ $0.00; 67,000 derivative/option shares @ $0.00 (as reported on the Form 4).
Vesting (per footnotes): RSUs vest over four years — 25% on each Feb 26 of 2027, 2028, 2029 and 2030. The option’s underlying shares vest 25% on Feb 26, 2027, then monthly in equal installments through Feb 26, 2030; all vesting is subject to continued service.
RSU settlement: Each RSU represents a contingent right to receive one share upon settlement for no consideration (per footnote).
Shares owned after the transaction: not specified in the provided filing excerpt.
No indication of a 10b5-1 plan, tax withholding sale, or late filing in the provided data.

Context

These awards are standard equity compensation for executives and do not indicate immediate buying or selling of company stock. The RSUs will convert to shares only as they vest; the option is a derivative award whose exercise terms (e.g., exercise price) are not detailed in the excerpt beyond the reported $0 acquisition entry. Such grants are typically intended for retention and compensation rather than a direct market signal.

Form 4

Period: 2026-02-26

Chief Scientific Officer

Transactions

Award
Common Stock
[F1]
2026-02-26+45,000→ 192,623 total
Award
Stock Option (right to buy)
[F2]
2026-02-26+67,000→ 67,000 total
Exercise: $13.38Exp: 2036-02-25→ Common Stock (67,000 underlying)

Footnotes (2)

[F1]The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
[F2]The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date.

Signature

/s/ Jared Freedberg, as attorney-in-fact for Angela M. Cacace|2026-03-02

1 file